Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-12-19
2006-12-19
Andres, Janet L. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S04400A, C424S130100, C424S145100, C436S501000, C435S007100, C530S300000, C530S351000, C530S387100, C530S388220
Reexamination Certificate
active
07151082
ABSTRACT:
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
REFERENCES:
patent: 5594114 (1997-01-01), Goodearl et al.
patent: 6303321 (2001-10-01), Tracey et al.
patent: 6448223 (2002-09-01), Tracey et al.
patent: 6468533 (2002-10-01), Tracey et al.
patent: 2003/0017155 (2003-01-01), Tracey et al.
patent: 2003/0113323 (2003-06-01), Tracey et al.
patent: 2004/0120953 (2004-06-01), Tracey et al.
patent: 1 079 849 (2002-01-01), None
patent: 362166897 (1986-01-01), None
patent: WO 99/59609 (1999-11-01), None
patent: WO 02/074337 (2002-09-01), None
patent: WO 02/092004 (2002-11-01), None
patent: WO 2004/004763 (2004-01-01), None
Janis Kuby, Immunology, 1992, p. 1.
Lotze-MT et al., Nature Reviews 5(331)2005.
Romani, M., et al., “Serological Analysis of Species Specificity in the High Mobility Group Chromosomal Proteins,”J. Biol. Chem., 254(8):2918-2922 (1979).
Bustin, M., et al., “Immunological Relatedness of High Mobility Group Chromosomal Proteins from Calf Thymus,”J. Biol. Chem., 253(5):1694-1699 (1978).
Rauvala, H. and Pihlaskari, R., “Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons,”J. Biol. Chem., 262(34):16625-16635 (1987).
Daston, M. M. and Ratner, N., “ Expression of P30, a Protein with Adhesive Properties, in Schwann Cells and Neurons of the Developing and Regenerating Peripheral Nerve,”J. Cell. Biol., 112(6):1229-1239 (1991).
Parkkinen, J., et al., “Amphoterin, the 30-kDa Protein in a Family of HMG1-type Polypeptides,”J. Biol. Chem., 268(26):19726-19738 (1993).
Sobajima, J. , et al., “High Mobility Group (HMG) Non-Histone Chromosomal Proteins HMG1 and HMG2 are Significant Target Antigens of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies in Autoimmune Hepatitis,”Gut, 44:867-873 (1999).
Ma W., et al., “Detection of Anti-Neutrophil Cytoplasmic Antibodies in MRL/Mp-lpr/lprMice and Analysis of their Target Antigens,”Autoimmunity, 32(4):281-291 (2000).
Banks, G. C., et al., “The HMG-I(Y) A·T-hook Peptide Motif Confers DNA-binding Specificity to a Structured Chimeric Protein,”J. Biol. Chem., 274(23):16536-16544 (1999).
Scaffidi, P., et al., “Release of Chromatin Protein HMGB1 by Necrotic Cells Triggers Inflammation,”Nature, 418:191-195 (2002).
Abaza, M.-S. I. and Atassi, M. Z., “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin,”J. Protein Chem., 11(5):433-444 (1992).
Colman, P. M., “Effects of Amino Acid Sequence Chamges on Antibody-Antigen Interactions,”Res. Immunol., 145(1):33-36 (1994).
Freeman, B. D., et al., “The Role of Inflammation in Sepsis and Septic Shock: A Meta-Analysis of Both Clinical and Preclinical Trials of Anti-Inflammatory Therapies,” inInflammation: Basic Principals and Clinical Correlates(John I. Gallin and Ralph Snyderman eds., Lippincott, Williams & Wilkins, Philadelphia, 3rded. 1999), pp. 965-975.
Lederman, S., et al., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody OKT,”Mol. Immunol., 28(11):1171-1181 (1991).
Czura, C., et al., “Dual Roles for HMGB1: DNA Binding and Cytokine,”J. Endotoxin Res., 7(4):315-321 (2001).
Wen, L., et al., “A Human Placental cDNA Clone that Encodes Nonhistone Chromosomal Protein HMG-1,”Nucleic Acids Res., 17(3):1197-1213 (1989).
Uesugi, H., et al., “Prevalence and Characterization of Novel pANCA, Antibodies to the High Mobility Group Non-Histone Chromosomal Proteins HMG1 and HMG2, in Systemic Rheumatic Diseases,”J. Rheumatol., 25(4):703-709 (1998).
Passalacqua, M., et al., “Stimulated Astrocytes Release High-Mobility Group 1 Protein, an Inducer of Lan-5 Neuroblastoma Cell Differentiation,”Neuroscience, 82(4):1021-1028 (1998).
Chou, D. K. H., et al., “Identity of Nuclear High-Mobility-Group Protein, HMG-1, and Sulfoglucuronyl Carbohydrate-Binding Protein, SBP-1, in Brain,”J. Neurochem., 77:120-131 (2001).
Imamura, T., et al., “Interaction with p53 Enhances Binding of Cisplatin-Modified DNA by High Mobility Group 1 Protein,”J. Biol. Chem., 276(10):7534-7540 (2001).
Ise, T., et al., “Transcription Factor Y-Box Binding Protein 1 Binds Preferentially to Cisplatin-Modified DNA and Interacts With Proliferating Cell Nuclear Antigen,”Cancer Res., 59:342-346 (1999).
Jung, F., et al., “Antibodies Against a Peptide Sequence Located in the Linker Region of the HMG-1/2 Box Domains in Sera From Patients With Juvenile Rheumatoid Arthritis,”Arthritis Rheum., 40(10):1803-1809 (1997).
Bianchi, M. E., et al., “Specific Recognition of Cruciform DNA by Nuclear Protein HMG1,”Science, 243:1056-1059 (1989).
Suda, T., et al., “A Novel Activity of HMG Domains: Promotion of the Triple-Stranded Complex Formation Between DNA Containing (GGA/TCC0)11and d(GGA)11Oligonucleotides,”Nucleic Acids Res., 24(23):4733-4740 (1996).
Ayer, L. M., et al., “Antibodies to HMG Proteins in Patients With Drug-Induced Autoimmunity,”Arthritis Rheum., 37(1):98-103 (1994).
Rauvala, H., et al., “The Adhesive and Neurite-Promotin Molecule p30: Analysis of the Amino-Terminal Sequence and Production of Antipeptide Antibodies That Detect p30 at the Surface of Neuroblastoma Cells and of Brain Neurons,”J. Cell Biol., 107(6):2293-2305 (1988).
Sobajima, J., et al., “Prevalence and Characterization of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (P-ANCA) Directed Against HMG1 and HMG2 in Ulcerative Colitis (UC),”Clin. Exp. Immunol., 111:402-407 (1998).
Yamada, S., et al., “High Mobility Group Protein 1 (HMGB1) Quantified by ELISA With a Monoclonal Antibody That Does Not Cross-React With HMGB2,”Clin. Chem., 49(9):1535-1537 (2003).
Falciola, L., et al., “High Mobility Group 1 Protein is Not Stably Associated with the Chromosomes of Somatic Cells,”J. Cell Biol., 137 (1):19-26 (1997).
Vanderbilt, J.N., et al., “Monoclonal Antibodies as Probes for the Complexity, Phylogency, and Chromatin Distribution of High Mobility Group Chromosomal Proteins 1 and 2,”J. Biol. Chem., 260(16) :9336-9345 (1985).
Bustin, M., et al., “Antigenic Determinants of High Mobility Group Chromosomal Proteins 1 and 2,”Biochem., 21 : 6773-6777 (1982).
Tsuneoka, M., et al., “Monoclonal Antibody Against Non-Histone Chromosomal Protein High Mobility Group 1 Co-Migrates With High Mobility Group 1 Into the Nucleus,”J. Biol. Chem., 261(4) :1829-1834 (1986).
Zhang, M. et al., “Tumor Necrosis Factor”, inThe Cytokine Handbook, (Academic Press Limited), Third Edition, pp. 517-547 (1998).
Johns, E.W., et al. “History, Definitions and Problems”, inThe HMG Chromosomal Problems, (Academic Press), London: Chapter 1, pp. 1-7 (1982).
Landsman, D., et al., “A Signature for the HMG-1 Box DNA-Binding Proteins”,BioEssays, 15(8) : 539-546 (1993).
Baxevanis, A.D., et al., “The HMG-1 Box Protein Family: Classification and Functional Relationships”,Nucleic Acids Res., 23(9) :1604-1613 (1995).
Merenmies, J., et
Tracey Kevin J.
Wang Haichao
Andres Janet L.
Brannock Michael
Hamilton Brook Smith & Reynolds P.C.
The Feinstein Institute for Medical Research
LandOfFree
Antagonists of HMG1 for treating inflammatory conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of HMG1 for treating inflammatory conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of HMG1 for treating inflammatory conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3715979